Linda Rickardson

1.4k total citations
28 papers, 1.1k citations indexed

About

Linda Rickardson is a scholar working on Molecular Biology, Oncology and Cancer Research. According to data from OpenAlex, Linda Rickardson has authored 28 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Molecular Biology, 13 papers in Oncology and 5 papers in Cancer Research. Recurrent topics in Linda Rickardson's work include Cancer therapeutics and mechanisms (4 papers), Ubiquitin and proteasome pathways (4 papers) and Cancer-related Molecular Pathways (4 papers). Linda Rickardson is often cited by papers focused on Cancer therapeutics and mechanisms (4 papers), Ubiquitin and proteasome pathways (4 papers) and Cancer-related Molecular Pathways (4 papers). Linda Rickardson collaborates with scholars based in Sweden, United States and Germany. Linda Rickardson's co-authors include Rolf Larsson, Joachim Gullbo, Peter Nygren, Mårten Fryknäs, Henrik Lövborg, Malin Wickström, Stig Linder, Anders Isaksson, Pádraig D’Arcy and Fredrik Öberg and has published in prestigious journals such as Nature Communications, Biochemical and Biophysical Research Communications and British Journal of Cancer.

In The Last Decade

Linda Rickardson

28 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Linda Rickardson Sweden 18 705 290 219 125 103 28 1.1k
Alok Ranjan United States 18 610 0.9× 242 0.8× 221 1.0× 114 0.9× 77 0.7× 38 1.1k
Paul S. Jones United Kingdom 20 611 0.9× 230 0.8× 159 0.7× 87 0.7× 79 0.8× 44 1.2k
Gelina S. Kopeina Russia 21 1000 1.4× 285 1.0× 184 0.8× 143 1.1× 68 0.7× 59 1.4k
Hui Xing China 22 768 1.1× 343 1.2× 387 1.8× 83 0.7× 116 1.1× 54 1.2k
Zhihong Wang China 22 1.2k 1.7× 237 0.8× 334 1.5× 68 0.5× 78 0.8× 81 1.6k
Raghavendra Gowda United States 20 695 1.0× 248 0.9× 211 1.0× 61 0.5× 59 0.6× 37 1.2k
Zhu Yuan China 24 1.0k 1.4× 394 1.4× 274 1.3× 129 1.0× 84 0.8× 68 1.4k
John P. Alao Sweden 18 1.0k 1.5× 435 1.5× 227 1.0× 83 0.7× 100 1.0× 33 1.6k
Shuang Cao China 19 573 0.8× 169 0.6× 289 1.3× 96 0.8× 79 0.8× 59 1.1k
Seyung Chung United States 18 844 1.2× 410 1.4× 181 0.8× 75 0.6× 106 1.0× 23 1.3k

Countries citing papers authored by Linda Rickardson

Since Specialization
Citations

This map shows the geographic impact of Linda Rickardson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Linda Rickardson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Linda Rickardson more than expected).

Fields of papers citing papers by Linda Rickardson

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Linda Rickardson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Linda Rickardson. The network helps show where Linda Rickardson may publish in the future.

Co-authorship network of co-authors of Linda Rickardson

This figure shows the co-authorship network connecting the top 25 collaborators of Linda Rickardson. A scholar is included among the top collaborators of Linda Rickardson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Linda Rickardson. Linda Rickardson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Rickardson, Linda, et al.. (2017). Evaluation of the antitumor activity of NOV202, a novel microtubule targeting and vascular disrupting agent. Drug Design Development and Therapy. Volume 11. 1335–1351. 5 indexed citations
2.
Eriksson, Anna, Syed Shams ul Hassan, Joachim Gullbo, et al.. (2015). Drug screen in patient cells suggests quinacrine to be repositioned for treatment of acute myeloid leukemia. Blood Cancer Journal. 5(4). e307–e307. 46 indexed citations
3.
Zhang, Xiaonan, Mårten Fryknäs, E Hernlund, et al.. (2014). Induction of mitochondrial dysfunction as a strategy for targeting tumour cells in metabolically compromised microenvironments. Nature Communications. 5(1). 3295–3295. 194 indexed citations
4.
Eriksson, Anna, Antonia Kalushkova, Malin Jarvius, et al.. (2013). AKN-028 induces cell cycle arrest, downregulation of Myc associated genes and dose dependent reduction of tyrosine kinase activity in acute myeloid leukemia. Biochemical Pharmacology. 87(2). 284–291. 12 indexed citations
5.
Jarvius, Malin, Mårten Fryknäs, Pádraig D’Arcy, et al.. (2013). Piperlongumine induces inhibition of the ubiquitin–proteasome system in cancer cells. Biochemical and Biophysical Research Communications. 431(2). 117–123. 50 indexed citations
6.
Fryknäs, Mårten, Joachim Gullbo, Xin Wang, et al.. (2013). Screening for phenotype selective activity in multidrug resistant cells identifies a novel tubulin active agent insensitive to common forms of cancer drug resistance. BMC Cancer. 13(1). 374–374. 8 indexed citations
7.
Dimberg, Lina Y., Anna Dimberg, Mårten Fryknäs, et al.. (2012). Stat1 activation attenuates IL-6 induced Stat3 activity but does not alter apoptosis sensitivity in multiple myeloma. BMC Cancer. 12(1). 318–318. 19 indexed citations
8.
Felth, Jenny, Pádraig D’Arcy, Caroline Haglund, et al.. (2012). Gambogic acid is cytotoxic to cancer cells through inhibition of the ubiquitin-proteasome system. Investigational New Drugs. 31(3). 587–598. 20 indexed citations
9.
Gullbo, Joachim, Mårten Fryknäs, Linda Rickardson, et al.. (2011). Phenotype-based drug screening in primary ovarian carcinoma cultures identifies intracellular iron depletion as a promising strategy for cancer treatment. Biochemical Pharmacology. 82(2). 139–147. 13 indexed citations
10.
Hassan, Saadia, Haile Mahteme, Jenny Felth, et al.. (2011). Novel activity of acriflavine against colorectal cancer tumor cells. Cancer Science. 102(12). 2206–2213. 54 indexed citations
11.
Fayad, Walid, Linda Rickardson, Caroline Haglund, et al.. (2011). Identification of Agents that Induce Apoptosis of Multicellular Tumour Spheroids: Enrichment for Mitotic Inhibitors with Hydrophobic Properties. Chemical Biology & Drug Design. 78(4). 547–557. 37 indexed citations
12.
Leuchowius, Karl‐Johan, Malin Jarvius, Malin Wickström, et al.. (2009). High Content Screening for Inhibitors of Protein Interactions and Post-translational Modifications in Primary Cells by Proximity Ligation. Molecular & Cellular Proteomics. 9(1). 178–183. 62 indexed citations
13.
Åleskog, Anna, Peter Nygren, Linda Rickardson, et al.. (2008). Rapamycin shows anticancer activity in primary chronic lymphocytic leukemia cellsin vitro, as single agent and in drug combination. Leukemia & lymphoma. 49(12). 2333–2343. 18 indexed citations
14.
Berndtsson, Maria, Mélanie Beaujouin, Linda Rickardson, et al.. (2008). Induction of the lysosomal apoptosis pathway by inhibitors of the ubiquitin‐proteasome system. International Journal of Cancer. 124(6). 1463–1469. 36 indexed citations
15.
Lövborg, Henrik, et al.. (2007). Identification and evaluation of potential anti-cancer drugs on human neuroendocrine tumor cell lines.. PubMed. 26(6B). 4125–9. 29 indexed citations
16.
Lindhagen, Elin, Linda Rickardson, Gary Elliott, et al.. (2007). Pharmacological profiling of novel non-COX-inhibiting indole-pyran analogues of etodolac reveals high solid tumour activity of SDX-308 in vitro. Investigational New Drugs. 25(4). 297–303. 7 indexed citations
17.
Fryknäs, Mårten, Sumeer Dhar, Fredrik Öberg, et al.. (2006). STAT1 signaling is associated with acquired crossresistance to doxorubicin and radiation in myeloma cell lines. International Journal of Cancer. 120(1). 189–195. 53 indexed citations
18.
Rickardson, Linda, Mårten Fryknäs, Caroline Haglund, et al.. (2006). Screening of an annotated compound library for drug activity in a resistant myeloma cell line. Cancer Chemotherapy and Pharmacology. 58(6). 749–758. 31 indexed citations
19.
20.
Lövborg, Henrik, Fredrik Öberg, Linda Rickardson, et al.. (2005). Inhibition of proteasome activity, nuclear factor-KB translocation and cell survival by the antialcoholism drug disulfiram. International Journal of Cancer. 118(6). 1577–1580. 102 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Alok Ranjan Breakdown of academic impact, for papers by Paul S. Jones Breakdown of academic impact, for papers by Gelina S. Kopeina Breakdown of academic impact, for papers by Hui Xing Breakdown of academic impact, for papers by Zhihong Wang Breakdown of academic impact, for papers by Raghavendra Gowda Breakdown of academic impact, for papers by Zhu Yuan Breakdown of academic impact, for papers by John P. Alao Breakdown of academic impact, for papers by Shuang Cao Breakdown of academic impact, for papers by Seyung Chung
Rankless by CCL
2026